MCID: GST044
MIFTS: 56

Gastritis malady

Categories: Gastrointestinal diseases, Infectious diseases

Aliases & Classifications for Gastritis

Aliases & Descriptions for Gastritis:

Name: Gastritis 12 29 52 42 14 69
Acute Gastric Mucosal Erosion 12 69
Erosive Gastropathy 12 69
Erosive Gastritis 12 69
Chronic Gastritis 14 69
Idiopathic Erosive/hemorrhagic Gastritis 69
Gastritis Erosive 52

Classifications:



External Ids:

Disease Ontology 12 DOID:4029
ICD10 33 K29.7
MeSH 42 D005756
NCIt 47 C26780
UMLS 69 C0017152

Summaries for Gastritis

Disease Ontology : 12 A stomach disease that is an inflammation of the lining of the stomach.

MalaCards based summary : Gastritis, also known as acute gastric mucosal erosion, is related to bacterial gastritis and secondary syphilis, and has symptoms including dyspepsia and gastric irritation. An important gene associated with Gastritis is GAST (Gastrin), and among its related pathways/superpathways are Toll Comparative Pathway and Defensins. The drugs Amoxicillin and Clarithromycin have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and colon, and related phenotype is digestive/alimentary.

Wikipedia : 71 Gastritis is inflammation of the lining of the stomach. It may occur as a short episode or may be of a... more...

Related Diseases for Gastritis

Diseases in the Gastritis family:

Viral Gastritis Bacterial Gastritis

Diseases related to Gastritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 228)
id Related Disease Score Top Affiliating Genes
1 bacterial gastritis 30.8 CDX2 CHGA CXCL8 DEFA5 DEFB1 DEFB4A
2 secondary syphilis 30.1 CHGA GAST
3 collagenous colitis 29.8 CXCL8 IL1B NOS2 PTGS2
4 autoimmune pancreatitis 29.7 CHGA GAST
5 histiocytosis 29.2 CXCL8 DEFB1 DEFB4A IL1B IL1RN
6 atrophic gastritis 12.4
7 autoimmune atrophic gastritis 12.1
8 collagenous gastritis 12.1
9 herpetic gastritis 12.1
10 alcoholic gastritis 12.0
11 granulomatous gastritis 12.0
12 gastritis, familial giant hypertrophic 12.0
13 chronic erosive gastritis 11.9
14 lymphocytic gastritis 11.9
15 eosinophilic gastritis 11.9
16 necrotizing gastritis 11.9
17 viral gastritis 11.9
18 cystic fibrosis with helicobacter pylori gastritis, megaloblastic anemia, and mental retardation 11.8
19 fungal gastritis 11.7
20 eosinophilic enteropathy 11.4
21 dyspepsia 11.1
22 lubani-al saleh-teebi syndrome 10.9
23 duodenitis 10.8
24 immunodeficiency 12 10.8
25 gastric cancer 10.5
26 gastroduodenitis 10.4
27 brain edema 10.3 CHGA GAST
28 gastric duplication cysts 10.3 CHGA GAST GHRL
29 senile reticular retinal degeneration 10.3 CXCL8 IL1B IL1RN
30 acinar cell cystadenocarcinoma 10.3 CHGA GAST GHRL
31 amyotrophic lateral sclerosis type 14 10.3 CXCL8 IL1B NOS2
32 autosomal recessive type iv ehlers-danlos syndrome 10.3 CXCL8 IL1B IL1RN
33 hidradenitis 10.3 CXCL8 IL1B PTGS2
34 acute eustachian salpingitis 10.3 CDX2 GAST S100A8
35 acquired thrombocytopenia 10.3 CXCL8 IL1B NOS2
36 skin conditions 10.3 CXCL8 IL1B IL1RN
37 peritoneal benign neoplasm 10.2 CDX2 CHGA
38 classic type lipoma 10.2 CXCL8 IL1B IL1RN
39 oculomotor nerve paralysis 10.2 CXCL8 IL1B
40 dystonia 10.2 CDX2 CHGA
41 mucositis 10.2
42 anal canal paget's disease 10.2 CDX2 CHGA
43 bullous retinoschisis 10.2 CXCL8 DEFB4A IL1B
44 post-vaccinal encephalitis 10.2 GAST SCT
45 pyelonephritis 10.2 CXCL8 IL1B NOS2
46 gastric ulcer 10.2
47 bile reflux 10.2
48 keratomalacia 10.2 CXCL8 IL1B NOS2
49 nasopharyngitis 10.2 CXCL8 DEFB1 IL1B
50 bone angioendothelial sarcoma 10.2 CXCL8 IL1B IL1RN PTGS2

Graphical network of the top 20 diseases related to Gastritis:



Diseases related to Gastritis

Symptoms & Phenotypes for Gastritis

UMLS symptoms related to Gastritis:


dyspepsia, gastric irritation

MGI Mouse Phenotypes related to Gastritis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.17 CDX2 GAST GHRL HRH2 NOS2 PTGS2

Drugs & Therapeutics for Gastritis

Drugs for Gastritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 260)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2 26787-78-0 33613 2171
2
Clarithromycin Approved Phase 4,Phase 2,Phase 3 81103-11-9 84029
3
Metronidazole Approved Phase 4,Phase 2,Phase 3 443-48-1 4173
4
Rabeprazole Approved, Investigational Phase 4,Phase 2,Phase 3 117976-89-3 5029
5
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3 73590-58-6 4594
6
Histamine Approved, Investigational Phase 4,Phase 1 75614-87-8, 51-45-6 774
7
Mianserin Approved Phase 4 24219-97-4 4184
8
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
9
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2 161796-78-7, 119141-88-7 4594 9579578
10
Lansoprazole Approved, Investigational Phase 4,Phase 3 103577-45-3 3883
11
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3 50-28-2 5757 53477783
12
Ethinyl Estradiol Approved Phase 4,Phase 3 57-63-6 5991
13
Moxifloxacin Approved, Investigational Phase 4,Phase 3 354812-41-2, 151096-09-2 152946
14
Norgestimate Approved Phase 4,Phase 3 35189-28-7 6540478
15
Sucralfate Approved Phase 4 54182-58-0
16
Ethanol Approved Phase 4,Phase 2 64-17-5 702
17
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
18
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
19 Titanium dioxide Approved Phase 4 13463-67-7
20
Potassium Citrate Approved, Vet_approved Phase 4
21
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
22
Levofloxacin Approved, Investigational Phase 4,Phase 3 100986-85-4 149096
23
Ofloxacin Approved Phase 4,Phase 3 82419-36-1 4583
24
Pantoprazole Approved Phase 4,Phase 3 102625-70-7 4679
25
Verapamil Approved Phase 4 52-53-9 2520
26
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
27
Ranitidine Approved Phase 4 66357-59-3, 66357-35-5 3001055
28
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
30
Ginseng Approved, Nutraceutical Phase 4 50647-08-0
31 Antacids Phase 4,Phase 3,Phase 2,Phase 1
32 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Antiparasitic Agents Phase 4,Phase 2,Phase 3
35 Antiprotozoal Agents Phase 4,Phase 2,Phase 3
36 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3
38 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
39 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40
Proton pump inhibitors Phase 4,Phase 3,Phase 2
41 Adrenergic Agents Phase 4
42 Adrenergic alpha-Antagonists Phase 4
43 Adrenergic Antagonists Phase 4
44 Antidepressive Agents Phase 4
45 Antidepressive Agents, Second-Generation Phase 4
46 Antidepressive Agents, Tricyclic Phase 4
47 Histamine Antagonists Phase 4,Phase 1
48 Histamine H1 Antagonists Phase 4
49
Histamine Phosphate Phase 4,Phase 1 51-74-1 65513
50 Neurotransmitter Agents Phase 4,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 194)
id Name Status NCT ID Phase
1 Concomitant Therapy of H. Pylori Unknown status NCT01922765 Phase 4
2 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4
3 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Unknown status NCT01464060 Phase 4
4 The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia Unknown status NCT02037776 Phase 4
5 Mirtazapine Versus Placebo in Functional Dyspepsia Unknown status NCT01240096 Phase 4
6 Clinical Effect of Rebamipide on Chronic Gastritis Completed NCT02393430 Phase 4
7 A Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis Completed NCT01284647 Phase 4
8 Efficacy and Safety of Eupasidin-s Tab.(EUPASIDIN-S) in Gastritis Patients Completed NCT02356679 Phase 4
9 A Study to Evaluate the Efficacy and of Stillen Tab. and to Demonstrate the Non-inferiority of Stillen Tab. Completed NCT01817556 Phase 4
10 Is a Reporting System for Gastritis or Duodenitis (Modified Lanza Scale) Reproducible? Completed NCT00852150 Phase 4
11 To Evaluate the Efficacy and Safety of Vitamin B12 Contains Extract of Lamb's Stomach in Treatment of Chronic Atrophic Gastritis (CAG) Completed NCT01474044 Phase 4
12 Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients Completed NCT01119768 Phase 4
13 Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer Completed NCT01190657 Phase 4
14 Importance of Cytokines in Peptic Ulcer Disease: Implications for Treatment Completed NCT00534443 Phase 4
15 Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy Completed NCT02633930 Phase 4
16 Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy Completed NCT02296021 Phase 4
17 High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication Completed NCT01888237 Phase 4
18 Efficacy and Safety of Probiotic Treatment as a Supportive Therapy in Eradication of H. Pylori Completed NCT01969331 Phase 4
19 A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Completed NCT01219764 Phase 4
20 Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection Completed NCT02835560 Phase 4
21 Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy Completed NCT01792700 Phase 4
22 Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori Completed NCT02352701 Phase 4
23 Efficacy of Banhasasim-tang on Functional Dyspepsia Completed NCT00987805 Phase 4
24 Lansoprazole Versus Mosapride for Functional Dyspepsia Completed NCT00663897 Phase 4
25 Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Recruiting NCT02175186 Phase 4
26 Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality Recruiting NCT02047994 Phase 4
27 Difference of Gastric Microbiota in the Process of Correa's Model. Recruiting NCT02833363 Phase 4
28 Intraluminal Therapy for Helicobacter Pylori Infection Recruiting NCT03124420 Phase 4
29 Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation Recruiting NCT02067182 Phase 4
30 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia Recruiting NCT02134405 Phase 4
31 Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety Active, not recruiting NCT02679508 Phase 4
32 The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study Not yet recruiting NCT02933229 Phase 4
33 Intragastric pH and Bismuth Effect for H. Pylori Eradication Not yet recruiting NCT02894892 Phase 4
34 Therapeutic Effect of Ursodeoxycholic Acid in Functional Dyspepsia Not yet recruiting NCT03004118 Phase 4
35 Lansoprazole Preventing Gastroduodenal Stress Ulcerations Terminated NCT00220909 Phase 4
36 Efficacy and Safety of Coenzyme Q10 in the Treatment of Statin-Associated Myalgia Terminated NCT00590408 Phase 4
37 The Clinical Significance of Acid Rebound in Functional Dyspepsia Terminated NCT01373970 Phase 4
38 Lansoprazole for Subgroups of Functional Dyspepsia Terminated NCT01040455 Phase 4
39 Esomeprazole Treatment for Patients With Lymphocytic Gastritis Unknown status NCT00455754 Phase 3
40 A Study to Evaluate the Efficacy and Safety of DA-5204 Unknown status NCT02282670 Phase 3
41 A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034 Unknown status NCT01813812 Phase 3
42 Esomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori Infection Unknown status NCT00455806 Phase 3
43 A Trial of Reconstruction After Distal Gastrectomy for Gastric Cancer Unknown status NCT01065688 Phase 3
44 Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection Unknown status NCT00197418 Phase 2, Phase 3
45 Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori Unknown status NCT00149084 Phase 3
46 Treatment of Knee Pain With Topical Diclofenac Cream 8% or Diclofenac Gel 1% Unknown status NCT02068859 Phase 3
47 Gabapentin in Functional Dyspepsia Refractory to Proton Pump Inhibition Unknown status NCT01052896 Phase 3
48 Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis Completed NCT00996788 Phase 3
49 Efficacy and Safety of Hizikia Fusiformis Extract in Subjects Showing Erosive Gastritis Completed NCT01689701 Phase 2, Phase 3
50 Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico. Completed NCT02726269 Phase 3

Search NIH Clinical Center for Gastritis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: gastritis

Genetic Tests for Gastritis

Genetic tests related to Gastritis:

id Genetic test Affiliating Genes
1 Gastritis 29

Anatomical Context for Gastritis

MalaCards organs/tissues related to Gastritis:

39
Testes, T Cells, Colon, Thyroid, Endothelial, B Cells, Spleen

Publications for Gastritis

Articles related to Gastritis:

(show top 50) (show all 1734)
id Title Authors Year
1
10-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori related chronic gastritis: a prospective randomized study in China. ( 28077338 )
2017
2
Upper gastrointestinal symptoms in autoimmune gastritis: A cross-sectional study. ( 28072728 )
2017
3
MicroRNAs 142-3p, miR-155 and miR-203 Are Deregulated in Gastric MALT Lymphomas Compared to Chronic Gastritis. ( 28031239 )
2017
4
Slow-release L-cysteine capsule prevents gastric mucosa exposure to carcinogenic acetaldehyde: results of a randomised single-blinded, cross-over study of Helicobacter-associated atrophic gastritis. ( 27806647 )
2017
5
Identification of Helicobacter pylori and the evolution of an efficacious childhood vaccine to protect against gastritis and peptic ulcer disease. ( 27701380 )
2017
6
Association between IL-1I^ polymorphisms and gastritis risk: A meta-analysis. ( 28151895 )
2017
7
Unusual presentation of infection by Helicobacter pylori: gastritis associated with Russell bodies, infrequent and poorly understood pathology. ( 27990837 )
2017
8
Diagnostic accuracy of nodular gastritis for H. pylori infection. ( 28031716 )
2017
9
NMR-based metabonomics and correlation analysis reveal potential biomarkers associated with chronic atrophic gastritis. ( 27697573 )
2017
10
Analyzing the influence of gastric intestinal metaplasia on gastric ulcer healing in Helicobacter pylori-infected patients without atrophic gastritis. ( 28049442 )
2017
11
The challenging diagnosis of autoimmune atrophic gastritis. ( 28040990 )
2017
12
The Diagnostic Value of Gastrin-17 Detection in Atrophic Gastritis: A Meta-Analysis. ( 27149493 )
2016
13
Gastritis and Gastric Ulcers in Working Dogs. ( 27092307 )
2016
14
Is It Rationale to Apply Strict Colonoscopic Surveillance in Patients with Helicobacter pylori Associated Chronic Atrophic Gastritis? ( 27784841 )
2016
15
Is Gastric Xanthelasma an Alarming Endoscopic Marker for Advanced Atrophic Gastritis and Intestinal Metaplasia? ( 27250981 )
2016
16
Differences between older and young patients with autoimmune gastritis. ( 27444719 )
2016
17
Braf, Kras and Helicobacter pylori epigenetic changes-associated chronic gastritis in Egyptian patients with and without gastric cancer. ( 27116958 )
2016
18
Acute gastritis associated with Epstein-Barr virus infection in a child. ( 28018450 )
2016
19
Spontaneous Gastric Perforation in a Case of Collagenous Gastritis. ( 26816680 )
2016
20
Comment on "Characteristics and Risk Factors of Helicobacter pylori Associated Gastritis: A Prospective Cross-Sectional Study in Northeast Thailand". ( 27598784 )
2016
21
OsmoPrep-associated Gastritis: A Histopathologic Mimic of Iron Pill Gastritis and Mucosal Calcinosis. ( 27454942 )
2016
22
CONVENTIONAL VIDEOENDOSCOPY CAN IDENTIFY HELICOBACTER PYLORI GASTRITIS? ( 27438029 )
2016
23
Dilemma of Timing of Administration of Non-Steroidal Anti-inflammatory Agents in Relation to Food in the Prevention of Gastritis: Debusting the Myth. ( 27480965 )
2016
24
(18)F-FDG uptake in the stomach on screening PET/CT: value for predicting Helicobacter pylori infection and chronic atrophic gastritis. ( 27756255 )
2016
25
SNP-SNP interactions of three new pri-miRNAs with the target gene PGC and multidimensional analysis of H. pylori in the gastric cancer/atrophic gastritis risk in a Chinese population. ( 26988755 )
2016
26
Polyautoimmunity in autoimmune gastritis. ( 27085391 )
2016
27
Characteristics and Risk Factors of Helicobacter pylori Associated Gastritis: A Prospective Cross-Sectional Study in Northeast Thailand. ( 27042174 )
2016
28
Kyoto global consensus report on Helicobacter pylori gastritis and its impact on Chinese clinical practice. ( 27164026 )
2016
29
Clinical and Endoscopic Features of Undifferentiated Gastric Cancer in Patients with Severe Atrophic Gastritis. ( 27086796 )
2016
30
Helicobacter pylori infection, chronic corpus atrophic gastritis and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort: a nested case-control study. ( 28032715 )
2016
31
An Unusual Presentation of Pseudothrombotic Microangiopathy in a Patient with Autoimmune Atrophic Gastritis. ( 27018160 )
2016
32
Endoscopic gastritis, serum pepsinogen assay, and Helicobacter pylori infection. ( 27604795 )
2016
33
Lymphocytic gastritis: clinical, endoscopic and histopathologic features. ( 27532536 )
2016
34
Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: a case series. ( 26965518 )
2016
35
Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. ( 27592118 )
2016
36
Decrease of serum total ghrelin in extensive atrophic gastritis: comparison with pepsinogens in histological reference. ( 26513345 )
2016
37
Draft Genome Sequence of Helicobacter suis Strain SNTW101, Isolated from a Japanese Patient with Nodular Gastritis. ( 27609915 )
2016
38
Superoxide dismutases in chronic gastritis. ( 26765960 )
2016
39
Gastritis - facts and doubts. ( 28053685 )
2016
40
Severe hemorrhagic gastritis after percutaneous endoscopic gastrostomy tube placement. ( 27065737 )
2016
41
Helicobacter pylori Infection with Atrophic Gastritis Is an Independent Risk Factor for Advanced Colonic Neoplasm. ( 27458180 )
2016
42
Helicobacter pylori vacA Genotypes in Chronic Gastritis and Gastric Carcinoma Patients from Macau, China. ( 27164143 )
2016
43
Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. ( 27704617 )
2016
44
Interferon-I^ promotes gastric lymphoid follicle formation but not gastritis in Helicobacter-infected BALB/c mice. ( 27895717 )
2016
45
Impact of Helicobacter pylori Immunoglobulin G Levels and Atrophic Gastritis Status on Risk of Metabolic Syndrome. ( 27851820 )
2016
46
Primary Eosinophilic Gastritis in a Child with Gastric Outlet Obstruction. ( 26768007 )
2016
47
A Clinicopathologic Study of Oral Changes in Gastroesophageal Reflux Disease, Gastritis, and Ulcerative Colitis. ( 27965506 )
2016
48
Helicobacter pylori-negative early gastric adenocarcinoma with complete intestinal mucus phenotype mimicking verrucous gastritis. ( 27977882 )
2016
49
A Panel of Serum Biomarkers (GastroPanelAr) in Non-invasive Diagnosis of Atrophic Gastritis. Systematic Review and Meta-analysis. ( 27798873 )
2016
50
Laparoscopic conversion of one anastomosis gastric bypass/mini gastric bypass to Roux-en-Y gastric bypass for bile reflux gastritis. ( 27825579 )
2016

Variations for Gastritis

Expression for Gastritis

Search GEO for disease gene expression data for Gastritis.

Pathways for Gastritis

Pathways related to Gastritis according to GeneCards Suite gene sharing:

(show all 16)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.09 CXCL8 IL1B NOS2 PTGS2
2
Show member pathways
12.02 CHGA DEFA5 DEFB1 DEFB4A S100A8
3
Show member pathways
11.98 CXCL8 DEFB4A IL1B NOS2
4
Show member pathways
11.89 CXCL8 DEFB4A IL1B PTGS2 S100A8
5 11.75 CXCL8 IL1B NOS2 PTGS2
6 11.72 CXCL8 IL1B NOS2
7 11.7 CXCL8 IL1B PTGS2
8 11.68 CXCL8 IL1B NOS2 PTGS2
9 11.65 CXCL8 IL1B NOS2
10 11.58 CXCL8 IL1B NOS2
11 11.36 CXCL8 NOS2 PTGS2
12
Show member pathways
11.21 PGA3 PGA4 PGA5
13
Show member pathways
11.06 CXCL8 IL1B NOS2 PTGS2
14 10.61 CXCL8 IL1B IL1RN PTGS2
15 10.36 GAST SCT
16 10.13 GAST HRH2

GO Terms for Gastritis

Cellular components related to Gastritis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.77 CHGA CXCL8 DEFA5 DEFB1 DEFB4A GAST
2 extracellular region GO:0005576 9.53 CHGA CXCL8 DEFA5 DEFB1 DEFB4A GAST
3 Golgi lumen GO:0005796 9.43 DEFA5 DEFB1 DEFB4A
4 multivesicular body lumen GO:0097486 9.33 PGA3 PGA4 PGA5

Biological processes related to Gastritis according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.93 CXCL8 IL1B IL1RN PTGS2 S100A8
2 immune response GO:0006955 9.91 CXCL8 DEFB1 DEFB4A HRH2 IL1B IL1RN
3 response to lipopolysaccharide GO:0032496 9.85 IL1B NOS2 PTGS2 S100A8
4 chemotaxis GO:0006935 9.83 CXCL8 DEFB1 DEFB4A S100A8
5 defense response GO:0006952 9.78 CXCL8 DEFA5 DEFB1 DEFB4A
6 autophagy GO:0006914 9.77 PGA3 PGA4 PGA5 PGC S100A8
7 defense response to Gram-positive bacterium GO:0050830 9.74 CHGA DEFB1 DEFB4A
8 neutrophil chemotaxis GO:0030593 9.73 CXCL8 IL1B S100A8
9 killing of cells of other organism GO:0031640 9.63 CHGA DEFA5 DEFB4A
10 defense response to bacterium GO:0042742 9.63 CHGA DEFA5 DEFB1 DEFB4A NOS2 S100A8
11 defense response to Gram-negative bacterium GO:0050829 9.62 CHGA DEFB1 DEFB4A NOS2
12 acute inflammatory response GO:0002526 9.58 DEFB1 S100A8
13 defense response to fungus GO:0050832 9.58 CHGA DEFA5 S100A8
14 protein catabolic process GO:0030163 9.56 PGA3 PGA4 PGA5 PGC
15 peptidyl-cysteine S-nitrosylation GO:0018119 9.51 NOS2 S100A8
16 positive regulation of fever generation GO:0031622 9.49 IL1B PTGS2
17 digestion GO:0007586 9.35 PGA3 PGA4 PGA5 PGC TFF2
18 antimicrobial humoral response GO:0019730 9.02 CHGA DEFA5 DEFB1 DEFB4A S100A8

Molecular functions related to Gastritis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.43 GAST GHRL SCT
2 interleukin-1 receptor binding GO:0005149 9.16 IL1B IL1RN
3 CCR6 chemokine receptor binding GO:0031731 8.96 DEFB1 DEFB4A
4 aspartic-type endopeptidase activity GO:0004190 8.92 PGA3 PGA4 PGA5 PGC

Sources for Gastritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....